Medical Necessity of Tirzepatide for Heart Failure with Preserved Ejection Fraction and Class 1 Obesity

Primary Evidence Supporting Approval

The American Diabetes Association recommends prioritizing tirzepatide over semaglutide for weight loss when greater magnitude of weight reduction is needed, with tirzepatide demonstrating superior weight loss (20.9%) compared to semaglutide (14.9%) 1, 2.
Tirzepatide is FDA-approved for chronic weight management in adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity, which this patient clearly meets with documented HFpEF, hypertension, and metabolic syndrome 1, 2.

Tirzepatide's dual GIP/GLP-1 receptor agonism provides cardioprotective effects through multiple mechanisms, including improved myocardial substrate utilization, anti-inflammatory and anti-atherosclerotic effects, reduced myocardial ischemia injury, lower systemic and pulmonary vascular resistance, and improved lipid profiles 1, 2.

Tirzepatide achieves mean weight loss of 20.9% at 72 weeks with the 15mg dose in non-diabetic patients with obesity, representing the most potent pharmacological weight loss option currently available 1, 2.
Even at lower doses, tirzepatide produces clinically meaningful weight reduction: the mean weight reduction across all doses is 8.47 kg compared to usual care 2.

The most common adverse effects are gastrointestinal (nausea 17-22%, diarrhea 13-16%, vomiting 6-10%), typically mild-to-moderate and transient, occurring primarily during dose escalation 1, 2.
Tirzepatide is contraindicated in patients with personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2—no such history is documented in this patient 1, 2.

Start tirzepatide 2.5mg subcutaneously once weekly for 4 weeks, then increase to 5mg weekly for 4 weeks, and further increase to 10mg or 15mg weekly if tolerated and additional weight loss is needed 2.
Evaluate treatment response at 12-16 weeks on the maximum tolerated therapeutic dose, expecting at least 4-5% body weight loss to justify continuation 1, 2.

Tirzepatide requires long-term continuous use to maintain weight loss benefits, with sudden discontinuation resulting in regain of one-half to two-thirds of weight loss within 1 year 2.
Weight management pharmacotherapy indicated for chronic therapy should be continued beyond reaching weight loss goals to maintain health benefits 3.